1. The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Myelodysplastic Syndromes: An Evidence-Based Review 
Denise M. Oliansky, Joseph H. Antin, John M. Bennett, H. Joachim Deeg, Christin Engelhardt, Kathleen V. Heptinstall, Marcos de Lima, Steven D. Gore, Ronald G. Potts, Lewis R. Silverman, Roy B. Jones, Philip L. McCarthy, Theresa Hahn 
Biology of Blood and Marrow Transplantation 
Volume 15, Issue 2, Pages (February 2009)
DOI: /j.bbmt
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Net benefit or loss of overall discounted life expectancy for the 4 IPSS risk groups shown above and below the x-axis. A net benefit for delaying transplantation is noted for low and int-1 risk group, whereas any delay in the time to transplantation is associated with a loss in survivorship in the higher risk groups. (Reprinted with permission, Cutler et al )
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
DFS among recipients of the HLA-identical related, HLA-identical unrelated, and HLA-nonidentical (related or unrelated) transplants. The + indicates censored patient. (Reprinted with permission, Deeg et al., 2002.)
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
OS by treatment arm for MDS. (Reprinted with permission, Couban et al., 2002.)
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
EFS in the RAEB/RAEB-t group according to the cell source. (Reprinted with permission, del Cañizo et al., 2003.)
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

6. Figure 5
Overall survival (OS) following CST and RIST in all patients. There was no significant difference in OS between CST and RIST (P = .25). (Reprinted with permission, Kojima et al )
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

7. Figure 6
Cumulative survival in MDS patients (n = 1405) classified according to the FAB group proposals. (Reprinted with permission, Germing et al., 2000.)
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

8. Figure 7
Cumulative survival in MDS patients (n = 1157) classified according to the new WHO proposals. (Reprinted with permission, Germing et al., 2000.)
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions